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DYRKHIPK2 (homeodomain-interacting protein kinase-2) binds to and phosphorylates, at Ser and Thr residues, a large
number of targets involved in cell division and cell fate decision in response to different physiological or stress
stimuli. Inactivation of HIPK2 has been observed in human andmouse cancers supporting its role as a tumor sup-
pressor. Despite the biological relevance of this kinase, very little is known on how HIPK2 becomes catalytically
active. Based on sequence homologies, HIPK2 has been taxonomically classiﬁed as a subfamily member of the
dual-speciﬁcity tyrosine-regulated kinases (DYRKs) and the activation-loop Y354 of HIPK2 has been found phos-
phorylated in different cells; however, the relevance of this Y phosphorylation is presently unknown. Here, we
show that HIPK2, which is extensively phosphorylated at S/T sites throughout its functional domains, becomes
catalytically active by autophosphorylation at the activation-loop Y354. In particular, we found that, in analogy
to DYRKs, HIPK2-Y354 phosphorylation is an autocatalytic event and its prevention, through Y354 substitution
with non-phosphorylatable amino acids or by using the kinase inhibitor purvalanol A, induces a strong reduction
of the HIPK2 S/T-kinase activity on different substrates. Interestingly, at variance from DYRKs, inhibition of
HIPK2-Y354 phosphorylation induces a strong out-of-target Y-kinase activity in cis and a strong cytoplasmic
relocalization of the kinase. Together, these results demonstrate that the catalytic activity, substrate speciﬁcity,
and subcellular localization of HIPK2 are regulated by autophosphorylation of its activation-loop Y354.
© 2013 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
HIPK2 is considered a nuclear S/T kinase that binds and phosphory-
lates a still enlarging body of targets involved in the regulation of cell sur-
vival and proliferation during development and in response to genotoxic
damage or hypoxia [1–4]. Among these HIPK2 targets, there are several
transcription and cotranscription factors, [5–8], signal transducers and
scaffold proteins [9–14], oncogenes and tumor suppressors [15–17],
and E3 components of SUMO and ubiquitin ligases [18–22]. The rele-
vance of these multiple HIPK2 interactions is highlighted by the ﬁnding
that HIPK2 can work as a haploinsufﬁcient tumor suppressor in mice
[23] and a few mechanisms of HIPK2 inactivation have been identiﬁed
in human cancers, such as HIPK2 forced cytoplasmic relocalizationence; IP, immunoprecipitation;
vA, purvalanol A; TCE, total cell
perimentale, Istituto Nazionale
ome, Italy. Tel.: +39 06 5266
(S. Soddu).
-NC-ND license.[15,24], HIPK2 mutations [25], and allele-speciﬁc loss of heterozygosity
[26].
HIPK2 is a member of the evolutionarily conserved family of
homeodomain-interacting protein kinases (HIPKs) that includes three
highly homologous S/T kinases originally identiﬁed for their capacity to
interact with homeodomain transcription factors (i.e., HIPK1, HIPK2,
andHIPK3) [27], and a fourthmember (HIPK4), that has been discovered
through in silico analysis of the human kinome [28]. Based on the homol-
ogy among catalytic domains, HIPKs have been taxonomically classiﬁed
as a subfamily of the dual-speciﬁcity tyrosine-regulated kinase (DYRK)
family that also includes two other subfamilies, the DYRK kinases and
the pre-mRNA processing 4 kinases [28]. Alignment of HIPKs' catalytic
domains with several DYRKs allowed the identiﬁcation of evolutionarily
conserved consensus motives, including the catalytic loop with a Lys
residue that contacts the primary phosphate (K221 in HIPK2), experi-
mentally shown to be required for HIPK2 kinase activity [27], and a Tyr
residue (Y354 in HIPK2) located in the context of the activation-loop
[29,30].
Phosphorylation of the activation-loop by upstream kinases, as in the
MAPK signaling cascade, or by autophosphorylation, as in the DYRK sub-
family [31], is one of the key regulatory mechanisms for catalytic activa-
tion of protein kinases [32,33]. Worth mentioning, DYRKs are deﬁned as
dual-speciﬁcity protein kinases because they become catalytically active
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while they phosphorylate their substrates only on Ser and Thr residues
[34].
Although different posttranslational modiﬁcations, such as sumoy-
lation, ubiquitylation, acetylation, and caspase cleavage, and interac-
tions with scaffold proteins have been shown to regulate the cellular
activities of HIPK2 [35,36], the mechanism through which HIPK2 be-
comes catalytically active is poorly understood. What is known is that
HIPK2 can autophosphorylate in vitro while its kinase-defective (KD)
derivative, obtained by substitution of the phosphate-contact Lys at po-
sition 221 with an Arg (HIPK2K221R), has a strongly reduced kinase ac-
tivity on both exogenous targets and HIPK2 itself [5,6,27]. Starting
from these observations, here we provide strong evidence that auto-
phosphorylation at the activation-loop Y354 promotes the catalytic ac-
tivation of HIPK2 and regulates its substrate speciﬁcity and subcellular
localization. Indeed, inhibition of Y354 phosphorylation promotes a
strong out-of-target Y autophosphorylation in cis that results in accu-
mulation of HIPK2 into cytoplasmic aggresomes, reminiscent of similar
observations in human cancers [15,24].
2. Materials and methods
2.1. Expression vectors and transfection
The following plasmids were employed: pGEX-HIPK2 [5]; pEGFP-
HIPK2, pEGFP-K221R [19]; pcDNA3GST-HIPK2 and pcDNA3GST-K221R
[37]. pEGFP-Y354F, pEGFP-Y354A, andpCDNA3GST-Y354Fwere obtained
by QuickChange site-directed mutagenesis (Stratagene). pcDNA3GST-
Y354F(Δ1050–1189) was obtained by SalI digestion of the pcDNA3GST-
Y354F vector to remove the 1050–1189 amino acid fragment. To obtain
pcDNA3GST-HIPK2(784–1189), DNA fragment 784–1189 of murine
Hipk2 cDNA was ampliﬁed from pBKS-clone#46 [5] by PCR and cloned
into pCDNA3GST vector as previously described [37]. To obtain pGEX-
HIPK2(158–557), pGEX-K221R(158–557) and pGEX-Y354F(158–557),
the 158–557 fragments were ampliﬁed from the corresponding pEGFP
vectors by PCR and cloned into EcoRI/XhoI digested pGEX6p-2rbs
(kindly provided by A. Musacchio). His-HIPK2(158–557) was cloned
from SalI-HindIII into the pQE30 expression vector (Qiagen) and puriﬁed
using Ni-NTA metal-afﬁnity chromatography (The Qiaexpressionist,
Qiagen). All constructs were controlled by sequencing. pEGFP-DYRK1A
and pEGFP-Y321F were kindly provided by W. Becker and pEGFP-NF-YA
by G. Piaggio. The expression vectors were transfected by Lipofectamine
LTX and Plus reagent (Invitrogen).
2.2. Cells, culture conditions, and recombinant vaccinia virus
Human H1299, HEK293, U2OS, RKO and HEL cells, hTert-
immortalized human ﬁbroblasts [17], and p53-null mouse embryo
ﬁbroblasts were cultured in DMEM or RPMI supplemented with 10%
heat-inactivated fetal bovine serum (Invitrogen). Purvalanol A, TBB
(4,5,6,7-tetrabromo-2-azabenzimidazole), and myelin basic protein
(MBP) were obtained from Sigma-Aldrich. The His-tagged kinase do-
main of HIPK2 expressed in Sf21 insect cells, His-HIPK2(158–557) was
purchased from Millipore, the Mito Tracker Red from Invitrogen, and
MG132 from Calbiochem. Recombinant vaccinia virus vTF7-3 carrying
the bacteriophage T7 gene 1, kindly provided by Dr. B. Moss, was prop-
agated in HEK293 cells and used as described [38].
2.3. His-puriﬁcation, GST-pulldown, immunoprecipitation, λPPase treatment
and kinase assay
Afﬁnity adsorption to Ni-NTA agarose (Qiagen) and Glutathione-
Sepharose 4 Fast Flow (GE Healthcare) were performed accordingly to
the manufacturer's instructions. For immunoprecipitation, total cell ex-
tracts (TCEs) were prepared in lysis buffer [50 mM Tris–HCl pH 7.5,
5 mM EDTA pH 8, 300 mM NaCl, 1% NP40, 50 mM NaF, and 2 mMNaOV4]. Dephosphorylation was performed by λPPase (New England
Biolabs). AfterλPPase treatment, the phosphatasewaswashed out, phos-
phatase inhibitors (Pierce) were added, and kinase assays performed as
reported [17].
2.4. Mass spectrometry (MS) of HIPK2 phosphorylated sites
Puriﬁed HIPK2 recombinant proteins were resolved by SDS-PAGE,
detected by Coomassie Colloidal Blue staining (Invitrogen) and the
appropriate bands were excised and subjected to in-gel digestions
by sequencing grade modiﬁed porcine trypsin (Promega) or chymo-
trypsin (Sigma-Aldrich) as described [39]. To recognize phosphorylat-
ed peptides, digestion mixtures were co-crystallized with the matrix,
α-cyano-4-hydroxycinnamic acid (Sigma-Aldrich) on the MALDI-TOF
plate. Analyses were performed by a Voyager-DE STR MALDI-TOF
(Applied Bio-systems) operating in reﬂectronmode. Spectrawere inter-
nally calibrated and processed by Data Explorer software.
To identify phosphorylated sites, peptides were analyzed by liquid
chromatography–tandem mass spectrometry (LC–MS/MS). Peptide
mixtures were separated using an Ultimate 3000 HPLC (DIONEX)
connected on line with a linear ion trap (LTQ, Thermo Electron).
Peptides were separated in a reverse phase, 10-cm capillary column.
A data-dependent strategy was used to fragment the ﬁve more in-
tense ions present in each full MS scan by collision-induced dissocia-
tion. Tandem mass spectra were interpreted through the SEQUEST
algorithm [40], taking into account the potential for phosphorylation
on Ser, Thr, or Tyr residues. A MS/MS was considered legitimately
matched with cross-correlation scores of 1.8, 2.5, and 3 respectively
for one, two, and three charged peptides and a probability cut-off for
randomized identiﬁcation of p b 0.001.
2.5. RNA extraction and quantitative real-time RT-PCR
RNA extraction and real-time RT-PCR were performed as described
[17].
2.6. Protein extraction and Western blotting
TCEs were prepared in lysis buffer [50 mM Tris–HCl (pH 8),
150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1% NP40, 1 mM
EDTA, and 2 mM Na3VO4] supplemented with protease-inhibitor mix
(Roche). Nuclear/cytoplasmic differential extractions were performed
using NE-PER™ Nuclear and Cytoplasmic Extraction Reagents (Thermo
Scientiﬁc) according to the manufacturer's instructions. Soluble and
insoluble fractions were obtained as described [41]. Proteins were
resolved by SDS-PAGE using NuPAGE® Novex Bis-Tris Gels (Invitrogen),
transferred onto nitrocellulose membranes (Bio-Rad), and analyzed
with the indicated antibodies (Abs). The following Abs were employed:
α-pTyr PY99 monoclonal Ab (moAb) (Santa Cruz Biotechnologies),
α-pTyr 4G10 moAb (Upstate), rabbit α-HIPK2 Ab (kindly provided
by M.L. Schmitz), α-alpha-tubulin moAb (Immunological Sciences),
α-GFP moAb (Santa Cruz Biotechnologies), rabbit α-HDAC-1 Ab
(Sigma-Aldrich), α-GST moAb (kindly provided by M. Fanciulli),
α-His moAb (Millipore), rabbit α-mouse IgG, HRP-conjugated goat
α-mouse and α-rabbit IgG (Cappel). Immuno-reactivity was detected
by the ECL-chemi-luminescence reaction (Amersham Corp).
2.7. In vitro translation
GST-HIPK2 was expressed in Reticulocyte Lysate TNT system
(Promega) using T7 RNA polymerase in a 2 h-reaction and puriﬁed
by afﬁnity adsorption to Glutathione-Sepharose (GE Healthcare).
TBB and purvalanol A were added prior to the initiation of transcription
at the indicated concentrations.
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Fig. 1. HIPK2 phosphorylated sites. A–B) Full-length wild-type GST-HIPK2 produced in E. coli (A) and human H1299 cells (B) were analyzed by MS (left panels) and LC–MS/MS
(right panels). Spectra of the peptides containing the activation-loop Y354 are reported. Squares in panels A and B indicate the peak corresponding to the phosphorylated peptide
containing Y354. C) KD GST-HIPK2K221R mutant was produced in human H1299 cells and analyzed by MS as in (B). The dotted square indicates the peak corresponding to the
unphosphorylated peptide containing Y354. D) Schematic representation of the distribution of phosphorylated sites on full-length wild-type GST-HIPK2 (eukaryotic GST-HIPK2)
and KD GST-HIPK2K221R puriﬁed from human cells (eukaryotic GST-K221R) and on full-length GST-HIPK2 puriﬁed from E. coli (prokaryotic GST-HIPK2). E) Schematic representation
of HIPK2 structural domains with the 23 phosphoresidues identiﬁed byMS in human cells. The sites found phosphorylated also in the recombinant HIPK2 produced in E. coli are indicated
with asterisks. N-ter: N-terminal domain; HID: Homeobox Interactive Domain; PEST: PEST sequence; AID: Auto-Inhibitory Domain; YH: Y and H rich domain.
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Fig. 2. HIPK2-Y354 phosphorylation is an autocatalytic event. A) The indicated proteins expressed and GST-puriﬁed from human H1299 cells were analyzed by WB with α-pTyr
PY99 and 4G10 Abs. Normalization was performed by WB with α-HIPK2 Ab. B) His-tagged HIPK2(158–557) produced and puriﬁed from insect cells were untreated (ﬁrst lane),
treated with ATP (second lane), treated with phosphatase (third lane), or treated with phosphatase, washed to remove phosphatase, and treated with ATP (fourth lane).
WB were performed with PY99 α-pTyr Ab. Normalization was performed with α-His Ab. C) His-tagged HIPK2(158–557) samples derived from E. coli were treated and analyzed
as in B. D–H) His-tagged HIPK2(158–557) produced and puriﬁed from insect cells was treated as in (B) and analyzed by MS (D, E, and F) and LC–MS/MS (G and H). Spectra of the
peptides containing the activation-loop Y354 are reported. Squares in D and F indicate the peak corresponding to the phosphorylated peptide containing Y354. Dotted square in
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Fig. 3. Effects of purvalanol A and TBB on HIPK2 kinase activity. A) Full-length GST-HIPK2
was in vitro translated with rabbit reticulocyte lysate in the presence of purvalanol A
(upper panel) or TBB (lower panel) at the indicated concentrations. In vitro translated
proteins were puriﬁed by GST-pulldown, resolved by SDS-PAGE, and immunoblotted
with PY99 α-pTyr and α-HIPK2 Abs. B) In vitro kinase assays of full-length GST-HIPK2
puriﬁed from humanH1299 cells onMBP substrate in the presence of increasing amounts
of TBB and purvalanol A.MBP phosphorylationwasmeasured evaluating [32P]-incorporation
upon SDS-PAGE and autoradiography. Data are shown asmeanwith standard deviation (SD)
of three independent experiments.
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For immunoﬂuorescence (IF) experiments, cells were seeded onto
poly-L-lysine coated coverslips, ﬁxed and permeabilized as empirically
predetermined for each Ab [4]. The following Abs were used: rabbit
α-calreticulin and rabbit α-LAMP2 (Afﬁnity BioReagents), α-GM130
moAb (BD Bioscences), rabbit α-γ-tubulin Ab (Sigma), α-ubiquitin
moAb (Santa Cruz), and α-HIPK2 moAb [17]. Appropriate secondary
FITC- or TRITC-conjugated Abs (Jackson Immuno Research Lab) were
employed. Fluorescence signals were recorded by Leica DMIRE2 micro-
scope equippedwith a Leica DFC 350FX camera and elaborated by Leica
FW4000 software (Leica).
3. Results and discussion
Although activation-loop Y residues of HIPKs were found phos-
phorylated in different conditions [42–44], it is actually unknown
whether they are phosphorylated by upstream kinase(s) or by auto-
catalytic events and whether their phosphorylation is relevant for
catalytic activation. To address the possible contribution of the
activation-loop Y354 phosphorylation on HIPK2 activity, we ﬁrst con-
ﬁrmed its phosphorylation status together with the phosphorylation
of other HIPK2 sites. Recombinant His- and GST-tagged HIPK2 pro-
teins [e.g., the kinase domain, the wild-type full-length protein or its
kinase defective (KD), HIPK2K221R derivative — Supplementary Fig.
S1] were expressed in prokaryotes (Escherichia coli) and eukaryotes
(insect Sf21 cells and human H1299 cells), puriﬁed, and analyzed by
MS and LC–MS/MS. The activation-loop Y354 was phosphorylated in
all the recombinant proteins we analyzed with the exception of the
KD HIPK2K221R mutant (Fig. 1A-C and data not shown), suggesting
that it might be an autophosphorylation site. In addition, we found
22 phosphorylated S/T sites distributed throughout the different
HIPK2 domains, some of which were maintained in the recombinant
protein expressed in prokaryotes (Fig. 1D, E and Supplementary
Table 1), indicating that HIPK2 autophosphorylates also on S/T sites.
Absence of detection in MS does not necessarily indicate absence of
phosphorylation, thus, we veriﬁed that HIPK2 autophosphorylates at Y
residue by performing WB analysis on the full-length wild-type HIPK2
and its KD mutant, HIPK2K221R, with two speciﬁc anti-phospho-tyrosine
(α-pTyr) Abs (Fig. 2A). To conﬁrm that the autophosphorylated Y is the
activation-loop Y354, we assessed the ability of an in vitro dephos-
phorylated HIPK2 to rephosphorylate Y354 in the presence of ATP. Since
efﬁcient dephosphorylation of DYRKs can be obtained only with truncat-
ed versions of the kinases [45], HIPK2(158–557) deletion mutant puriﬁed
from insect cells (Fig. 2B), or from E. coli (Fig. 2C) were employed.
α-pTyr WB showed that λPPase treatment efﬁciently dephosphorylates
His-HIPK2(158–557) at Y residue, whereas λPPase removal and subsequent
kinase reaction rescues α-pTyr immunoreactivity (Fig. 2B and C) as well
as catalytic activity on an exogenous substrate, i.e., MBP (Supplementary
Fig. S2). Next, similarly dephosphorylated/rephosphorylated samples
were analyzed by MS. A peak matching a singly phosphorylated
ACVSTYLQSR peptide (m/z: 1264.5 vs the expected 1184.5 of the
nonphosphorylated peptide) was present in the untreated sample
(Fig. 2D), disappeared in the λPPase treated sample (Fig. 2E), and
reappeared upon rephosphorylation (Fig. 2F). LC–MS/MS fragmenta-
tion demonstrated that Y354 is the phosphorylated residue (Fig. 2G
and H), together with S434 (data not shown)while no other phosphor-
ylated Ys were detected in any of these conditions. Taken together,
these data show that HIPK2-Y354 phosphorylation is an autocatalytic
event.
In the DYRK family, phosphorylation of the activation-loop Y takes
place in cis on the nascent, ribosome-bound protein. In addition, it has
been proposed that after release from the ribosome, the mature kinase
loses the Y autophosphorylation activity andbecomes a S/T kinase toward
exogenous substrates [46]. Thus, we assessed whether HIPK2-Y354 be-
haves as a DYRK activation-loop Y and its phosphorylation is requiredfor HIPK2 catalytic activity on itself and its substrates. To this aim, we
ﬁrst evaluated HIPK2 sensitivity to purvalanol A and TBB, two small-
molecules that differentially inhibit DYRKs' activity. In particular,
purvalanol A, but not TBB, inhibits the activation-loop Y autophosphoryl-
ation in rabbit reticulocyte lysates, while both molecules inhibit trans-
phosphorylation on exogenous substrates [46]. α-pTyr WB of in vitro
translated HIPK2 showed that Y autophosphorylation is inhibited by
purvalanol A but not TBB (Fig. 3A). In contrast, both small molecules
inhibited HIPK2 trans-phosphorylation onMBP, as assessed by in vitro ki-
nase assays (Fig. 3B). These results show that the catalytic structure of
HIPK2 able to autophosphorylate on Y residue is different from the cata-
lytic structure that phosphorylate exogenous substrates on S/T residues
and, in analogy with DYRKs, support the hypothesis that activation-loop
Y354 autophosphorylation might take place on nascent HIPK2 protein.
To further evaluate whether Y354 phosphorylation is required for
the S/T kinase activity of HIPK2, we compared the full-length wild-
type HIPK2 and its KD HIPK2K221R mutant with the HIPK2Y354F deriva-
tive in which the activation-loop Y354 is non-phosphorylatable. In
vitro kinase assays showed that substitution of the activation-loop Y
with F almost abolished the ability of HIPK2 to phosphorylate the
non-speciﬁc substrate MBP (Fig. 4A) and strongly inhibited phosphory-
lation of two speciﬁc substrates, p53 and p63 (Fig. 4B and C). These data
support the idea that phosphorylation of the activation-loop Y354 is
responsible for the catalytic activation of HIPK2. However, when we
assessed the three GST-puriﬁed proteins from human cells for their
autophosphorylation, HIPK2Y354F exhibited an intermediate activity
between HIPK2 and the KD HIPK2K221R mutant (Fig. 4D), indicating
that inhibition of Y354 phosphorylation does not abolish per se the
catalytic activity of the kinase. Of relevance, comparable results were
obtained by assessing the kinase activity of full-length wild-type
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inhibit Y354 phosphorylation on the nascent protein, as conﬁrmed by
α-pTyr WB (Fig. 4E and F). Surprisingly, when the same proteins were
analyzed by anti-pTyrWB, an increased immunoreactivitywas detected
in the GST-puriﬁed HIPK2Y354F compared with wild-type HIPK2 and its
KD mutant (Fig. 5A) and in the wild-type IVT-HIPK2 translated in the
presence of purvalanol A, washed and incubated in the presence of
ATP (Fig. 5B). Together with the data reported above, these results sug-
gest that the residual autophosphorylation is due, at least in part, to
Y-kinase activity. Indeed, a direct analysis of the phosphorylation pat-
tern of HIPK2Y354F by MS showed the appearance of a novel phosphor-
ylated Y residue at position 1186 (Fig. 5C and Supplementary Fig. S3A).
Since we never detected Y1186 phosphorylation in wild-type HIPK2,
even upon incubation with ATP to maximize autophosphorylation
(data not shown), these results suggest that the activation-loop Y354
autophosphorylation prevents aberrant Y phosphorylation activity.
To further characterize this behavior, we assessed the Y kinase ac-
tivity of HIPK2Y354F upon deletion of its C-terminal region (aa1050–
1189) that contains the newly phosphorylated Y1186 residue. Similar
deletion mutants of wild-type HIPK2 and its KD mutant were ana-
lyzed as control, and showed no signiﬁcant difference before and
after incubation in the presence of ATP, as assessed by α-pTyr WB
(Fig. 5D, lower panel) and MS (data not shown). α-pTyr WB showed no
reduction in the ability of HIPK2Y354F(Δ1050–1189) to autophosphorylate
Y residues (Fig. 5D, upper panel), indicating the maintenance of a strong
and out-of-target Y-kinase activity. Indeed, comparable results were
obtained by employing the sole HIPK2 kinase domain, i.e., GST-
HIPK2(158–557), in the wild-type form or with the K221R or the Y354Fki
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Fig. 4. Impairment of HIPK2-Y345 phosphorylation affects HIPK2 kinase ability. A–C) MBP, p
from human H1299 cells were assessed upon in vitro kinase assays in the presence of [γ-3
above. (A–D) Indicative autoradiographies with the relative Coomassie blue stainings are
at least three independent experiments. E) Full-length wild-type HIPK2 was in vitro tran
purvalanol A. Samples translated in the presence of purvalanol A were washed to remove
absence of MBP. Autoradiographies and densitometric analysis and Coomassie staining are
reticulocyte lysate in the presence or absence of 150 μM of purvalanol A, as in E. Samples w
The level of pY of each sample was analyzed by WB with PY99 α-pTyr Ab. Normalization w
densitometric values of the autophosphorylation and MBP phosphorylation shown in E.mutations puriﬁed from bacteria, analyzed by α-pTyr WB in the ab-
sence of incubation with ATP (Supplementary Fig. S1 and Fig. 5E),
showing that different Y residues can be the target of autophosphoryl-
ation in the absence of activation-loop Y354 phosphorylation.
Finally, we asked whether the persistent, out-of-target Y auto-
phosphorylation of HIPK2Y354F takes place in cis or in trans. To this
aim, the HIPK2 C-terminal region containing the Y1186 phosphory-
lation site, HIPK2(784–1189) (Supplementary Fig. S1) puriﬁed from E. coli,
was used as substrate for HIPK2, HIPK2Y354F, and HIPK2K221R in in vitro
kinase assays in the presence of [γ-32P]-ATP or cold ATP. In the ﬁrst
case, autoradiography showed that HIPK2 and HIPK2Y354F are able to
trans-phosphorylate HIPK2(784–1189), thoughHIPK2Y354F was less efﬁcient
than wild-type HIPK2 (Fig. 5F, graphic and upper panels). In the second
case, α-pTyr WB showed no immunoreaction with any of the samples
(Fig. 5F, lower panels), indicating that Y1186 autophosphorylation by
HIPK2Y354F occurs in cis, while the trans-phosphorylation detected by
autoradiography applies to S/T residues. Similar results were obtained
by employing the HIPK2K221R(158–557) as substrate (Supplementary Fig.
S3B and S3C).
Altogether, these results indicate that, similarly to DYRKs, phos-
phorylation of the activation-loop Y354 of HIPK2 is an autocatalytic
event and regulates the S/T kinase activity. However, at variance
with DYRKs, in which inhibition of the activation-loop Y autophos-
phorylation results in a complete loss of Y-kinase activity [45,46], im-
pairment of HIPK2-Y354 phosphorylation results in the acquisition of
a strong out-of-target Y-kinase activity.
To evaluate the functional implications of impairing HIPK2-Y354 au-
tophosphorylation,we transfected humanU2OS cells with EGFP-taggedautoradiography
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HIPK2Y354F). As expected [47], EGFP-HIPK2 showed a prevalent nucle-
ar, dotted distribution and, to a lower extent, a nuclear/cytoplasmic,B
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as in (A). Representative images are shown in (I) and percentages of cells with different
1451F. Siepi et al. / Biochimica et Biophysica Acta 1833 (2013) 1443–1453represented by dot-like structures and larger aggregations (Fig. 6A and
C). These different subcellular distributions were conﬁrmed by WB
analyses performed on nuclear and cytoplasmic fractions (Fig. 6D). In
addition, comparable results were obtained i) employing an EGFP-
HIPK2Y345A derivative, in which the non-phosphorylatable F residue
was substituted with an A, to exclude amino acid-based artifacts
(Fig. 6B and C); ii) using a lower amount of plasmid DNA (Supplementary
Fig. S3A-D); iii) transfecting cells from a different line (i.e., human RKO
cells) (Supplementary Fig. S3C and D); and iv) inhibiting Y autophospho-
rylation of wild-type HIPK2with purvalanol A. In the last experiment, we
assessed the subcellular distribution of EGFP-HIPK2 expressed in U2OS
cells (Fig. 6E and F) or of the endogenous HIPK2 in human ﬁbroblasts
(Fig. 6G and H), in the presence or absence of purvalanol A or TBB. Treat-
ment with purvalanol A, but not TBB, induced a strong cytoplasmic delo-
calization of wild-type HIPK2 (Fig. 6E–H, and data not shown) but not of
the transcription factor NF-YA employed as control (Supplementary Fig.
S3E). Furthermore, we observed that the cytoplasmic delocalization isA
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Fig. 7. Cytoplasmic HIPK2 accumulates into aggresomes. A) U2OS cells were transiently tra
immunostained with the indicated Abs. Hoechst was used to visualize DNA. Colocalization w
of at least 200 cells scored are shown. B, C) U2OS cells were transfected with EGFP-HIPK
harvested and divided into aliquots to obtain total mRNA, TCEs, soluble and insoluble fraction
and insoluble fractions were resolved by SDS-PAGE and immunoblotted with α-HIPK2 Ab.
transfected with EGFP-HIPK2-expressing vector, treated for 16 h with 5 μM MG132 and a
that were resolved by SDS-PAGE and analyzed by WB with the indicated Abs (D); and ﬁxed
with EGFP-HIPK2 was evaluated by EGFP autoﬂuorescence (E) and percentages of cells with
analyzed and percentages of cytoplasmic dots and aggresomes are reported. G) Human HEL
Representative images of at least 200 cells scored are shown.characteristic of HIPK2, since the homologous DYRK1AY321F derivative
maintains a nuclear localization (Supplementary Fig. S3F). Of note, de-
spite the absence of Y354 phosphorylation described above, the KD
HIPK2K221R mutant retains a nuclear distribution (Fig. 6I and L) [47].
This behavior suggests that the cytoplasmic relocalization observed
upon inhibition of the sole Y354 phosphorylation might be due to the
out-of-target Y phosphorylation, rather than to a generalized inhibition
of HIPK2 kinase activity. Indeed, this hypothesis was strongly supported
by the observation that a double HIPK2K221R/Y354F mutant exhibits a nu-
clear localization comparable with the single HIPK2K221R mutant (Fig. 6I
and L). This result might explain why DYRK1AY321F derivative, that at
variance from HIPK2 loses its Y-kinase activity, maintains a nuclear
localization.
To further characterize the HIPK2 subcellular distribution ob-
served upon impairment of Y354 phosphorylation, colocalization
analyses were performed with organelle-speciﬁc Abs. We found that
EGFP-HIPK2Y354F does not colocalize with calreticulin, GM130, andC
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nsfected with EGFP-Y354F-expressing vector. After 24 h from transfection, cells were
ith EGFP-Y354F was evaluated through EGFP autoﬂuorescence. Representative images
2, EGFP-Y354F or EGFP-empty vector (e.v.). After 24 h from transfection, cells were
s. HIPK2 and Y354F mRNA levels were analyzed by real-time RT-PCR (B). TCEs, soluble,
Normalization was obtained with α-tubulin Ab (C). D–F) U2OS cells were transiently
nalyzed by WB and IF as follows: harvested to obtain soluble and insoluble fractions
and immunostained with α-ubiquitin Ab and Hoechst to visualize DNA. Colocalization
different subcellular localization are reported in (F). At least 300 cells per sample were
leukemia cells were immunostained with α-HIPK2 (red) and α-ubiquitin (green) Abs.
1452 F. Siepi et al. / Biochimica et Biophysica Acta 1833 (2013) 1443–1453Mitotracker, respectively employed as markers of the endoplasmic
reticulum, Golgi apparatus, and mitochondria (Supplementary Fig.
S4). In contrast, colocalization was observed with the lysosomal
marker LAMP2 and with ubiquitin, while γ-tubulin immunostaining
showed proximity of the EGFP-HIPK2Y354F aggregations with micro-
tubule organizing centers (Fig. 7A). This distribution is compatible
with that of the intracellular “storage bins” known as aggresomes
[48], usually involved in the clearance of misfolded or aggregated
proteins [49]. Since aggresome-stored proteins are partially insoluble
[41], we compared the solubility of HIPK2 and its HIPK2Y354F deriva-
tive. To this aim, TCEs were obtained from U2OS cells transfected to
express comparable amounts of EGFP-HIPK2 and EGFP-HIPK2Y354F
mRNAs (Fig. 7B), and both soluble and insoluble fractions were ana-
lyzed by WB for the presence of the kinases. As shown in Fig. 7C,
whereas wild-type HIPK2 was almost completely present in the solu-
ble fraction, about 50% of HIPK2Y354F was found in the insoluble one.
This behavior is not a mutation-linked artifact since we could induce
cytoplasmic delocalization and aggresome storage of wild-type EGFP-
HIPK2 by cell treatment with MG132 to block the proteasome. As
shown by WB for soluble and insoluble fractions (Fig. 7D) and by
immunoﬂuorescence with an anti-ubiquitin Ab (Fig. 7E and F), a strong
increase in the presence of HIPK2 in the insoluble fraction and a shift
from nuclear, ubiquitin-negative dots to cytoplasmic, ubiquitin-positive
aggregates were observed in the MG132-treated cells.
The HIPK2 aggresome accumulation induced by inhibition of Y354
phosphorylation is reminiscent of HIPK2 delocalization observed in
human breast carcinomas and leukemias [15,24]. Interestingly, IF
analyses of endogenous HIPK2 in tumor cells with high cytoplasmic
HIPK2 expression, such as HEL leukemia cells, showed a signiﬁcant
colocalization of HIPK2 and ubiquitin in aggresome-like structures
(Fig. 7G), suggesting that aggresome formation, such as that induced
by inhibition of HIPK2-Y354 phosphorylation, might contribute to
inactivate the tumor-suppressive function(s) of HIPK2 in human
cancers.4. Conclusion
The phosphorylation of one or two amino acids in the kinase
activation-loop, a sequence of 12-37 residues conserved among mem-
bers of the same family, is one of themechanisms throughwhich protein
kinases regulate their own activity [32]. Activation-loop phosphorylation
might be catalyzed by upstream kinases or occurs by autophosphoryl-
ation in cis or in trans. In this study, we identify the activation-loop
Y354 of HIPK2 as a critical autophosphorylation site to acquire kinase ac-
tivation, substrate speciﬁcity, and subcellular localization. Indeed, differ-
ently from DYRKs, impairment of HIPK2-Y354 autophosphorylation
results in a strong out-of-target Y-kinase activity in cis that cause a sig-
niﬁcant cytoplasmic relocalization with aggresome formation. Further
studies will be needed to determine whether this activity pertains to a
dysfunctional state of HIPK2, leading to inactivation of its tumor-
suppressing functions, for example through mutations in the
activation-loop or overexpression/iperactivation of tyrosine phospha-
tases and pseudo-phosphatases. Alternatively, it might belong to a
physiological state of HIPK2, involved in regulating its stability and/or
activity. The dephosphorylation/rephosphorylation data obtained with
the isolated kinase domain suggest that HIPK2 can fold properly and
its dephosphorylation does not impair the Y354 kinase activity. In
contrast, impairment of Y354 autophosphorylation during translation,
as mimicked by the Y354F mutant or purvalanol A treatment, might
inhibit a proper folding of HIPK2, or induce a different folding,
resulting in out-of target Y auto-phosphorylation. The resemblance
of HIPK2 accumulation upon inhibition of Y354 phosphorylation
with the cytoplasmic delocalization of HIPK2 in human cancers
suggests that neoplasias might be used as experimental systems to
discriminate between these possibilities.Acknowledgements
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